Navigation Links
Treating safety research like other clinical studies slows progress
Date:5/13/2008

Progress in patient safety research could slow to a crawl unless regulators work out a host of ethical issues, Johns Hopkins researchers assert in an upcoming opinion piece.

We cant apply a clinical paradigm to patient safety research. It just isnt the right fit, says Nancy Kass, Sc.D., deputy director for public health at the Johns Hopkins Berman Institute of Bioethics and an author of the article.

The piece, published in the June issue of The Joint Commission Journal on Quality and Patient Safety, was sparked by a 2006 study led by Peter Pronovost, M.D., Ph.D., professor of anesthesiology, critical care medicine, and surgery at the Johns Hopkins University School of Medicine. In the study, Pronovost, an expert on patient safety, implemented a checklist in intensive care units (ICUs) at 67 Michigan hospitals aimed at preventing bloodstream infections whenever doctors insert catheters.

The results were markedly positive: Bloodstream infections from catheters fell by two-thirds, and on average, infection rates in the ICUs went from 4 percent to zero. Over the course of the study, the program saved more than 1,500 lives and nearly $200 million.

Shortly after the studys results were published, however, an anonymous complaint led to a federal reexamination of the ethical oversight of the study. As in most human research, Pronovosts study had been reviewed by an institutional review board (IRB)an internal group required at most research institutions to use federal regulations to make sure research studies protect the welfare of human subjects.

Because Pronovosts study enforced safety measures already known to be effective, and because no data were ever collected from patients by name, the Johns Hopkins IRB classified Pronovosts study as exempt from further IRB review. This designation meant that informed consent was not necessary from the ICU patients and that IRB review from each of the 67 Michigan hospitals that participated wasnt required. However, after the anonymous complaint, the federal Office for Human Research Protections, a branch of the U.S. Department of Health and Human Services that oversees IRBs, determined that patient consent and Michigan hospital IRB review should have taken place.

According to Kass, who served for more than 10 years on a Johns Hopkins IRB and is an expert in the ethics of human research, such a decision ignores the differences between patient safety research of this sort and other types of research that include riskier and more burdensome interventions and procedures, such as human trials for new drugs.

While well-informed consent is crucial for all patients participating in new drug research, for example, it may not be necessary for studies like Pronovosts research, in which the proposed interventiona checklist to remember to follow steps, all known to make the ICU saferis virtually risk-free, where data are lumped together so individual patients names and information are never collected, and where the consent process may be burdensome to very sick patients. Also, according to Kass, since many small hospitals dont have IRBs, requiring every hospital to get an IRB review for patient safety evaluations would hinder many hospitals from participating in these studies and contributing their experiences to widespread evaluations.

All of us want to make sure that patients are protected in any type of research, said Kass, but it is also critical to recognize which studies are low risk and should easily move through the system, and which ones are high risk and require considerably more scrutiny.

Kass adds that working through these issues is crucial to advancing patient safety research, a field that has the potential to greatly advance public health.

When the public thinks about important medical research, they might think about a cure for a horrible disease. I think the average person has heard very little about the fact that many more people die in the hospital of medical errors than they do from lots of diseases, she says.

There is an ethical imperative to do patient safety research, she adds. We need to find a review system that works so that important research in this field wont be compromised.


'/>"/>

Contact: Christen Brownlee
cbrownlee@jhmi.edu
410-955-7832
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
2. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
3. Treating diabetes during pregnancy can break link to childhood obesity
4. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
5. Treating Diabetes During Pregnancy Could Lead to Thinner Kids
6. Family-based treatment more effective than supportive psychotherapy in treating bulimia
7. Treating depression may improve recovery of heart rate variability following coronary syndromes
8. Antidepressant shows early promise in treating agitation and psychotic symptoms of dementia
9. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
10. Stem cells show promise for treating Huntingtons disease
11. Treating obstructive sleep apnea, preventing heart attacks and strokes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that your clothes ... not alone. According to the Center for Disease Control and Prevention (CDC), 34.9% of ... and certain types of cancer, some of the leading causes of preventable death. ...
(Date:2/8/2016)... Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently retired ... also was the American Cancer Society’s 2015 CEO of the Year , helped ...
(Date:2/8/2016)... ... ... Discover the Rocky Mountain region’s longest running and impressive garden and home show ... to see the most incredible gardens and home improvement experts that attend this amazing ... Center - 700 14th St. Denver CO, is an exciting event that Performance Mobility ...
(Date:2/8/2016)... Vegas, NV (PRWEB) , ... February 08, 2016 , ... ... on February 9th, 10th and 11th, 2016 in honor of his birthday on February ... and true happiness. Mahendra Trivedi is known by over 250,000 people from over ...
(Date:2/7/2016)... Texas (PRWEB) , ... February 07, 2016 , ... ... new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and information ... MyDecision™ combines three elements to cut the cost of providing employee healthcare benefits ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... NORRITON, Pa. , Feb. 8, 2016 /PRNewswire/ ... of November Research Group (NRG),s pharmacovigilance technology ... pharmacovigilance system-related consulting services and an Oracle Argus ... compliance services to Life Sciences companies. ... strengthens and expands HighPoint,s life sciences capabilities and ...
(Date:2/8/2016)... Switzerland and PALO ALTO, Calif. , Feb. ... and chemical manufacturing, and Kodiak Sciences Inc., a biopharmaceutical ... of retinal disease, announced today agreements for the clinical ... will manufacture material at multiple sites, including Slough (UK), ... --> --> Retinal diseases, such as ...
(Date:2/8/2016)... 2016  Avista Pharma Solutions ("Avista Pharma") announced today ... Financial Officer (CFO). Mr. Setzer is a finance and ... various roles within growing technology and life science companies. ... Executive Director of Finance at INC Research, a publicly ... . Previously, Mr. Setzer served as CFO of ...
Breaking Medicine Technology: